[43] In vitro and in Vivo models of bacterial biofilms
This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform fil...
Gespeichert in:
Veröffentlicht in: | Methods in Enzymology 1999, Vol.310, p.577-595 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 595 |
---|---|
container_issue | |
container_start_page | 577 |
container_title | Methods in Enzymology |
container_volume | 310 |
creator | Yasuda, Hiroshi Koga, Tetsufumi Fukuoka, Takashi |
description | This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform film formation, uniform reproducibility, and the ability to be investigated quantitatively. However, the ability to mimic a highly complicated in vivo condition is desirable in an in vitro model. There have been relatively few reports on in vivo models of biofilm growth. One of the most difficult challenges to overcome is to devise a durable infection model. Generally, it takes several days for infected bacteria to form biofilms in an infected tissue or organ, and it takes several days longer to investigate the therapeutic effect of a drug after the biofilm mode of growth of the infected bacteria has been established. Ideally, the infection should continue in a stable condition for more than 7–10 days. Respiratory tract infections, urinary tract infections, infective endocarditis, foreign body infections, and so forth are typical infectious diseases in which the biofilm mode of bacterial growth is sometimes characteristic. Therefore, these diseases should be taken into account in making a useful in vivo experimental biofilm infection model. |
doi_str_mv | 10.1016/S0076-6879(99)10045-4 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_69233654</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0076687999100454</els_id><sourcerecordid>69233654</sourcerecordid><originalsourceid>FETCH-LOGICAL-c433t-c8b6959cdc91d4fc8e49ac61d531a24af0188b9b2729d556903784f18674b66a3</originalsourceid><addsrcrecordid>eNo9kMlKBDEURYMD2g6foGQluijNy5yVSOPQ0ODCYSMSUkkKIjW0leoG_95qbb2bt7iHB_cgdALkEgjIqydClCykVubcmAsghIuCb6EJCKEKZbTeRgcEKGhKAdQOmvzz--g45w8yBsaG0z20D0RwpSlMkHzj7B3PWrxKQ99h1wacWvyaVh1uuhDrjLsKl84PsU-uxmXqqlQ3-QjtVq7O8XhzD9HL3e3z9KGYP97PpjfzwnPGhsLrUhphfPAGAq-8jtw4LyEIBo5yVxHQujQlVdQEIaQhTGlegZaKl1I6dojOfv8u-u5zGfNgm5R9rGvXxm6ZrTSUMSn4CJ5uwGXZxGAXfWpc_2X_lo7A9S8wboqrFHubfYqtjyH10Q82dGmE7dq1_XFt1-6sMfbHteXsGxUJarA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69233654</pqid></control><display><type>article</type><title>[43] In vitro and in Vivo models of bacterial biofilms</title><source>ScienceDirect eBooks</source><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Yasuda, Hiroshi ; Koga, Tetsufumi ; Fukuoka, Takashi</creator><creatorcontrib>Yasuda, Hiroshi ; Koga, Tetsufumi ; Fukuoka, Takashi</creatorcontrib><description>This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform film formation, uniform reproducibility, and the ability to be investigated quantitatively. However, the ability to mimic a highly complicated in vivo condition is desirable in an in vitro model. There have been relatively few reports on in vivo models of biofilm growth. One of the most difficult challenges to overcome is to devise a durable infection model. Generally, it takes several days for infected bacteria to form biofilms in an infected tissue or organ, and it takes several days longer to investigate the therapeutic effect of a drug after the biofilm mode of growth of the infected bacteria has been established. Ideally, the infection should continue in a stable condition for more than 7–10 days. Respiratory tract infections, urinary tract infections, infective endocarditis, foreign body infections, and so forth are typical infectious diseases in which the biofilm mode of bacterial growth is sometimes characteristic. Therefore, these diseases should be taken into account in making a useful in vivo experimental biofilm infection model.</description><identifier>ISSN: 0076-6879</identifier><identifier>ISBN: 0121822117</identifier><identifier>ISBN: 9780121822118</identifier><identifier>EISSN: 1557-7988</identifier><identifier>DOI: 10.1016/S0076-6879(99)10045-4</identifier><identifier>PMID: 10547821</identifier><language>eng</language><publisher>United States: Elsevier Science & Technology</publisher><subject>Animals ; Anti-Bacterial Agents - administration & dosage ; Bacterial Physiological Phenomena ; Bacteriological Techniques ; Biocompatible Materials ; Biofilms - drug effects ; Biofilms - growth & development ; Diffusion Chambers, Culture ; Escherichia coli - physiology ; Humans ; In Vitro Techniques ; Male ; Microscopy, Electron, Scanning ; Models, Biological ; Phagocytosis ; Pseudomonas aeruginosa - physiology ; Rats ; Rats, Wistar ; Staphylococcus epidermidis - physiology ; Stents - adverse effects</subject><ispartof>Methods in Enzymology, 1999, Vol.310, p.577-595</ispartof><rights>1999</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c433t-c8b6959cdc91d4fc8e49ac61d531a24af0188b9b2729d556903784f18674b66a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0076687999100454$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,775,776,780,789,3446,3537,4010,11267,27900,27901,27902,45786,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10547821$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yasuda, Hiroshi</creatorcontrib><creatorcontrib>Koga, Tetsufumi</creatorcontrib><creatorcontrib>Fukuoka, Takashi</creatorcontrib><title>[43] In vitro and in Vivo models of bacterial biofilms</title><title>Methods in Enzymology</title><addtitle>Methods Enzymol</addtitle><description>This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform film formation, uniform reproducibility, and the ability to be investigated quantitatively. However, the ability to mimic a highly complicated in vivo condition is desirable in an in vitro model. There have been relatively few reports on in vivo models of biofilm growth. One of the most difficult challenges to overcome is to devise a durable infection model. Generally, it takes several days for infected bacteria to form biofilms in an infected tissue or organ, and it takes several days longer to investigate the therapeutic effect of a drug after the biofilm mode of growth of the infected bacteria has been established. Ideally, the infection should continue in a stable condition for more than 7–10 days. Respiratory tract infections, urinary tract infections, infective endocarditis, foreign body infections, and so forth are typical infectious diseases in which the biofilm mode of bacterial growth is sometimes characteristic. Therefore, these diseases should be taken into account in making a useful in vivo experimental biofilm infection model.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Bacterial Physiological Phenomena</subject><subject>Bacteriological Techniques</subject><subject>Biocompatible Materials</subject><subject>Biofilms - drug effects</subject><subject>Biofilms - growth & development</subject><subject>Diffusion Chambers, Culture</subject><subject>Escherichia coli - physiology</subject><subject>Humans</subject><subject>In Vitro Techniques</subject><subject>Male</subject><subject>Microscopy, Electron, Scanning</subject><subject>Models, Biological</subject><subject>Phagocytosis</subject><subject>Pseudomonas aeruginosa - physiology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Staphylococcus epidermidis - physiology</subject><subject>Stents - adverse effects</subject><issn>0076-6879</issn><issn>1557-7988</issn><isbn>0121822117</isbn><isbn>9780121822118</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMlKBDEURYMD2g6foGQluijNy5yVSOPQ0ODCYSMSUkkKIjW0leoG_95qbb2bt7iHB_cgdALkEgjIqydClCykVubcmAsghIuCb6EJCKEKZbTeRgcEKGhKAdQOmvzz--g45w8yBsaG0z20D0RwpSlMkHzj7B3PWrxKQ99h1wacWvyaVh1uuhDrjLsKl84PsU-uxmXqqlQ3-QjtVq7O8XhzD9HL3e3z9KGYP97PpjfzwnPGhsLrUhphfPAGAq-8jtw4LyEIBo5yVxHQujQlVdQEIaQhTGlegZaKl1I6dojOfv8u-u5zGfNgm5R9rGvXxm6ZrTSUMSn4CJ5uwGXZxGAXfWpc_2X_lo7A9S8wboqrFHubfYqtjyH10Q82dGmE7dq1_XFt1-6sMfbHteXsGxUJarA</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Yasuda, Hiroshi</creator><creator>Koga, Tetsufumi</creator><creator>Fukuoka, Takashi</creator><general>Elsevier Science & Technology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>1999</creationdate><title>[43] In vitro and in Vivo models of bacterial biofilms</title><author>Yasuda, Hiroshi ; Koga, Tetsufumi ; Fukuoka, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c433t-c8b6959cdc91d4fc8e49ac61d531a24af0188b9b2729d556903784f18674b66a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Bacterial Physiological Phenomena</topic><topic>Bacteriological Techniques</topic><topic>Biocompatible Materials</topic><topic>Biofilms - drug effects</topic><topic>Biofilms - growth & development</topic><topic>Diffusion Chambers, Culture</topic><topic>Escherichia coli - physiology</topic><topic>Humans</topic><topic>In Vitro Techniques</topic><topic>Male</topic><topic>Microscopy, Electron, Scanning</topic><topic>Models, Biological</topic><topic>Phagocytosis</topic><topic>Pseudomonas aeruginosa - physiology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Staphylococcus epidermidis - physiology</topic><topic>Stents - adverse effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yasuda, Hiroshi</creatorcontrib><creatorcontrib>Koga, Tetsufumi</creatorcontrib><creatorcontrib>Fukuoka, Takashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Methods in Enzymology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yasuda, Hiroshi</au><au>Koga, Tetsufumi</au><au>Fukuoka, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>[43] In vitro and in Vivo models of bacterial biofilms</atitle><jtitle>Methods in Enzymology</jtitle><addtitle>Methods Enzymol</addtitle><date>1999</date><risdate>1999</risdate><volume>310</volume><spage>577</spage><epage>595</epage><pages>577-595</pages><issn>0076-6879</issn><eissn>1557-7988</eissn><isbn>0121822117</isbn><isbn>9780121822118</isbn><abstract>This chapter focuses on several methods that have been developed in the laboratory to form bacterial biofilm models in vitro and in vivo, as well as several methods developed to investigate the nature of biofilm bacteria. Ideal properties sought in an in vitro bacterial biofilm model are uniform film formation, uniform reproducibility, and the ability to be investigated quantitatively. However, the ability to mimic a highly complicated in vivo condition is desirable in an in vitro model. There have been relatively few reports on in vivo models of biofilm growth. One of the most difficult challenges to overcome is to devise a durable infection model. Generally, it takes several days for infected bacteria to form biofilms in an infected tissue or organ, and it takes several days longer to investigate the therapeutic effect of a drug after the biofilm mode of growth of the infected bacteria has been established. Ideally, the infection should continue in a stable condition for more than 7–10 days. Respiratory tract infections, urinary tract infections, infective endocarditis, foreign body infections, and so forth are typical infectious diseases in which the biofilm mode of bacterial growth is sometimes characteristic. Therefore, these diseases should be taken into account in making a useful in vivo experimental biofilm infection model.</abstract><cop>United States</cop><pub>Elsevier Science & Technology</pub><pmid>10547821</pmid><doi>10.1016/S0076-6879(99)10045-4</doi><tpages>19</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0076-6879 |
ispartof | Methods in Enzymology, 1999, Vol.310, p.577-595 |
issn | 0076-6879 1557-7988 |
language | eng |
recordid | cdi_proquest_miscellaneous_69233654 |
source | ScienceDirect eBooks; MEDLINE; Elsevier ScienceDirect Journals |
subjects | Animals Anti-Bacterial Agents - administration & dosage Bacterial Physiological Phenomena Bacteriological Techniques Biocompatible Materials Biofilms - drug effects Biofilms - growth & development Diffusion Chambers, Culture Escherichia coli - physiology Humans In Vitro Techniques Male Microscopy, Electron, Scanning Models, Biological Phagocytosis Pseudomonas aeruginosa - physiology Rats Rats, Wistar Staphylococcus epidermidis - physiology Stents - adverse effects |
title | [43] In vitro and in Vivo models of bacterial biofilms |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T11%3A34%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%5B43%5D%20In%20vitro%20and%20in%20Vivo%20models%20of%20bacterial%20biofilms&rft.jtitle=Methods%20in%20Enzymology&rft.au=Yasuda,%20Hiroshi&rft.date=1999&rft.volume=310&rft.spage=577&rft.epage=595&rft.pages=577-595&rft.issn=0076-6879&rft.eissn=1557-7988&rft.isbn=0121822117&rft.isbn_list=9780121822118&rft_id=info:doi/10.1016/S0076-6879(99)10045-4&rft_dat=%3Cproquest_pubme%3E69233654%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69233654&rft_id=info:pmid/10547821&rft_els_id=S0076687999100454&rfr_iscdi=true |